# AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma

> **NCT05985694** · PHASE1,PHASE2 · COMPLETED · sponsor: **Advagene Biopharma Co. Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Eosinophilic Asthma

## Interventions

- **DRUG:** AD17002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05985694
- **Lead sponsor:** Advagene Biopharma Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-27
- **Primary completion:** 2025-01-28
- **Final completion:** 2025-04-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05985694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05985694, "AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05985694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*